- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
PNV
ASX
Week ended 07 Aug 2026
Weekly Investor Report
PolyNovo Limited · Healthcare · Medical Devices
Latest close
0.88 AUD
1.2%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -11.6% below the Trend Line and sits at 7.6% of its 52-week range. The latest completed week returned 1.2%, after a -13.8% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal.
Setup score
17
out of 100
Latest Close
0.88 AUD
7 Aug 2026
1W Return
1.2%
latest completed week
4W Return
-13.8%
short-term follow-through
12W Return
-26.8%
quarterly tape
Trend Breadth
13.5%
7 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
1.2%
Latest completed week; four-week move -13.8%.
Indicator stack
7/4
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
53/100
23 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -11.6% below the Trend Line and sits at 7.6% of its 52-week range. The latest completed week returned 1.2%, after a -13.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1512-week average 0.25
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.15Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -13.8% over four weeks, -26.8% over 12 weeks, and -23.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year7
Trend breadth13.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.42Latest activity-pressure read.
Pressure change-485.6%Four-week change in activity pressure.
Leadership-25.68Latest relative-leadership reading.
RS change-122.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2025
Field coverage 82%
Model confidence 42%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength12/100Blend of value, momentum, and quality. Underlying universe rank 89; rank 1 is best.
Value2/100Relative valuation strength. Underlying universe rank 99; rank 1 is best.
Quality85/100Profitability and accounting quality. Underlying universe rank 16; rank 1 is best.
Momentum11/100Medium-term price momentum. Underlying universe rank 90; rank 1 is best.
Growth98/100Revenue and earnings growth. Underlying universe rank 3; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 45.7x Price divided by trailing earnings.
- Price / sales
- 4.8x Market value relative to trailing revenue.
- EV / EBITDA
- 56.3x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -1.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 95.9% Gross profit retained from each unit of revenue.
- Operating margin
- 3.5% Operating profit retained from revenue.
- Free-cash-flow margin
- -8.5% Free cash flow generated from revenue.
- Return on invested capital
- 5.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 23.3% Latest one-year revenue growth.
- EPS growth
- 150.9% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -1471.9% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -1.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment53/100
Weighted news tone is neutral across 23 relevant articles.
6 positive · 15 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-47.4%Distance below the 52-week high.
13-week volatility8.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2611 weeks finished lower.
Best week+18.3%Week of 15 May.
Worst week-13.5%Week of 5 Jun.
Latest week+1.2%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains7
Flat weeks2
Modest losses6
Sharp losses5
Recent vol8.8%13-week weekly-return volatility.
Base vol7.4%52-week weekly-return volatility.
Up/down split24/26Count of positive and negative weeks in the 52-week window.
Average skew5.8% / -5.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorAU Healthcare
4-week rank85 / 100
Group average-0.9%
Trend breadth25.0%
Trend25.0%active weekly trend signals
MD58.0%positive activity pressure
RS26.0%positive relative leadership
Four-week leaders
IndustryAU Medical Devices
4-week rank20 / 26
Group average-3.3%
Trend breadth19.2%
Trend19.2%active weekly trend signals
MD30.8%positive activity pressure
RS26.9%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape18/100
Trend, activity pressure, participation, and risk combine to a 18/100 tape read.
Indicator analysis23/100Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 1/12.
Activity pressure 0.15; No reversal markers Factors28/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 60; Small Cap Core rank 99 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment53/100Weighted news tone is neutral across 23 relevant articles.
Polynovo Target Price Cut 5.1% to A$1.48/Share by Morgans>PNV.AU Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 0.88 AUD | 1.2% | 0.99 AUD | 1.58 AUD | -0.42 | -25.68 | 10.2M | Off |
| 31 Jul 2026 | 0.86 AUD | 1.2% | 1.00 AUD | 1.58 AUD | -0.26 | -24.59 | 11.8M | Off |
| 24 Jul 2026 | 0.85 AUD | -12.8% | 1.01 AUD | 1.59 AUD | -0.15 | -24.25 | 18.8M | Off |
| 17 Jul 2026 | 0.98 AUD | -3.4% | 1.03 AUD | 1.59 AUD | -0.14 | -14.08 | 4.9M | Off |
| 10 Jul 2026 | 1.01 AUD | 3.6% | 1.04 AUD | 1.60 AUD | -0.07 | -11.53 | 5.7M | Off |
| 3 Jul 2026 | 0.98 AUD | 7.7% | 1.04 AUD | 1.60 AUD | -0.07 | -15.17 | 2.1M | Off |
| 26 Jun 2026 | 0.91 AUD | -9.0% | 1.05 AUD | 1.60 AUD | 0.10 | -20.87 | 2.4M | Off |
| 19 Jun 2026 | 1.00 AUD | 3.6% | 1.06 AUD | 1.61 AUD | 0.56 | -14.14 | 2.2M | Off |
| 12 Jun 2026 | 0.96 AUD | -8.5% | 1.07 AUD | 1.61 AUD | 0.91 | -17.27 | 3.7M | Off |
| 5 Jun 2026 | 1.05 AUD | -13.5% | 1.07 AUD | 1.61 AUD | 1.29 | -8.06 | 9.5M | Off |
| 29 May 2026 | 1.22 AUD | 7.5% | 1.08 AUD | 1.62 AUD | 1.33 | 4.54 | 24.2M | Off |
| 22 May 2026 | 1.14 AUD | -5.0% | 1.08 AUD | 1.62 AUD | 1.07 | -2.12 | 24.6M | Off |
| 15 May 2026 | 1.20 AUD | 18.3% | 1.09 AUD | 1.62 AUD | 0.76 | 3.00 | 21.2M | Off |
| 8 May 2026 | 1.01 AUD | 1.5% | 1.09 AUD | 1.62 AUD | 0.44 | -14.57 | 8.6M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.